FDA official labels UniQure's Huntington's gene therapy as 'failed'

• The FDA is requiring UniQure to conduct a randomized, placebo-controlled trial, rejecting the company's use of an external control database to measure patient outcomes
• UniQure claims a placebo-controlled study is unethical because it would require patients to undergo hours-long sham brain surgery under general anesthesia, but the FDA official disputed this characterization
• UniQure's stock has fallen 58% this year amid the dispute, though it rose more than 10% on Thursday following the FDA's public comments

Summary: FDA Official Labels UniQure's Huntington's Gene Therapy as 'Failed'

Key Development:

A senior FDA official publicly called UniQure's Huntington's disease gene therapy a "failed treatment," marking an escalation in a contentious dispute between the biotech company and the regulator.

Core Issue:

The FDA is requiring UniQure to conduct a new placebo-controlled clinical trial to demonstrate the therapy's effectiveness. The treatment is administered directly into the brain, and the FDA disputes UniQure's claim that a traditional randomized, double-blind study would be unethical due to requiring patients to undergo sham brain surgery under general anesthesia for hours.

FDA's Position:

• The official stated UniQure's original trial "failed years ago" and accused the company of attempting a "distorted or manipulated comparison" using external control data instead of proper clinical studies
• The FDA claims it "never agreed to accept this distorted comparison" and never assured approval based on the company's external control methodology
• The agency maintains it must evaluate actual data before making approval commitments

Company Dispute:

UniQure has accused the FDA of reversing its previous stance that the company's clinical trial data using an external database (measuring disease progression without treatment) would be sufficient for approval consideration.

Market Impact:

• UniQure stock rose over 10% Thursday following the developments
• Shares have declined 58% year-to-date as of Thursday afternoon

Broader Context:

This dispute occurs amid growing criticism of the FDA for recent drug application rejections, with some companies alleging the agency has reversed previous guidance. FDA Commissioner Marty Makary recently commented on rare disease therapies, indirectly referencing this case.